Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 11,520,000 shares, a growth of 10.3% from the June 30th total of 10,440,000 shares. Currently, 19.0% of the shares of the stock are short sold. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 9.8 days.
Day One Biopharmaceuticals Trading Down 5.8 %
Shares of NASDAQ DAWN opened at $14.31 on Thursday. The stock has a market cap of $1.25 billion, a P/E ratio of -5.70 and a beta of -1.51. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $18.07. The business’s fifty day simple moving average is $14.00 and its 200-day simple moving average is $14.84.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.70. The company had revenue of $8.19 million during the quarter, compared to analyst estimates of $0.90 million. On average, equities analysts forecast that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on DAWN
Insider Activity
In other news, insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $16.37, for a total value of $163,700.00. Following the completion of the sale, the insider now directly owns 1,164,662 shares in the company, valued at $19,065,516.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $16.37, for a total value of $163,700.00. Following the completion of the sale, the insider now directly owns 1,164,662 shares in the company, valued at $19,065,516.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Samuel C. Blackman sold 2,267 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $36,453.36. Following the completion of the sale, the insider now owns 1,171,081 shares of the company’s stock, valued at $18,830,982.48. The disclosure for this sale can be found here. Insiders sold 73,300 shares of company stock worth $1,181,765 over the last ninety days. Corporate insiders own 8.40% of the company’s stock.
Hedge Funds Weigh In On Day One Biopharmaceuticals
Large investors have recently bought and sold shares of the business. Quest Partners LLC purchased a new position in Day One Biopharmaceuticals in the fourth quarter valued at $29,000. Quintet Private Bank Europe S.A. grew its holdings in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Day One Biopharmaceuticals during the second quarter worth about $113,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Day One Biopharmaceuticals by 352.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock worth $147,000 after buying an additional 7,841 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Day One Biopharmaceuticals during the fourth quarter worth about $156,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Further Reading
- Five stocks we like better than Day One Biopharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 AI Stocks That You Can Buy and Hold Forever
- Comparing and Trading High PE Ratio Stocks
- As The Magnificent 7 Stumble, Pivot to These 3 Growth Stocks
- 3 Stocks to Consider Buying in October
- Joby Aviation Stock: The Case for Upside Just Got Stronger
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.